| Identification | Back Directory | [Name]
1,3,5-Triazine-2,4-diamine,1,6-dihydro-N,N,6-trimethyl-,(+)-(9CI) | [CAS]
775351-65-0 | [Synonyms]
IMegliMin
EMD 387008
R-IMegliMin
Emd 387008 hcl
EMD 387008/R-Imeglimin
EMD 387008 (R-IMEGLIMIN) HCL
(2S)-N6,N6,2-trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine
1,3,5-Triazine-2,4-diamine,1,6-dihydro-N,N,6-trimethyl-,(+)-(9CI)
1,3,5-Triazine-2,4-diamine, 3,6-dihydro-N2,N2,6-trimethyl-, (6R)- | [Molecular Formula]
C6H13N5 | [MDL Number]
MFCD19443705 | [MOL File]
775351-65-0.mol | [Molecular Weight]
155.2 |
| Chemical Properties | Back Directory | [Boiling point ]
239.9±23.0 °C(Predicted) | [density ]
1.29±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
11.65±0.40(Predicted) |
| Hazard Information | Back Directory | [Uses]
Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function[1]. | [in vivo]
Imeglimin (200 mg/kg b.i.d. by oral gavage during the last 6 weeks of HFHSD feeding) significantly decreases hyperglycemia, restores normal glucose tolerance, and improves insulin sensitivity[1]. | Animal Model: | Male C57BL/6JOlaHsd mice (4 weeks old)[1] | | Dosage: | 200 mg/kg | | Administration: | Oral gavage; b.i.d.; 6 weeks | | Result: | A slight decrease in body weight and food intake associated with some diarrhea was observed but only during the first few days of treatment. |
| [References]
[1] Vial G, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrialfunction in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015 Jun;64(6):2254-64. DOI:10.2337/db14-1220
[2] Detaille D, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016 Jan 18;2:15072. DOI:10.1038/cddiscovery.2015.72 |
|
|